Comparative Study Between Serum Level of Lysophosphatidic Acid and CA-125 in Epithelial Ovarian Cancer

Background: The aim of this study is to assess the diagnostic value of lysophosphatidic acid (LPA) in epithelial ovarian cancer (EOC) patients in comparison with CA125. Methods: The study included 41 women with EOC and 41 women with benign ovarian tumor. Serum CA-125 and LPA levels were measured and correlated with histopathological examination results. Results: Ovarian cancer patients have increased LPA and cancer antigen CA-125 levels compared to patients with benign ovarian tumor (LPA: ovarian cancer vs. benign ovarian tumor: 2.43 ± 1.69 vs. 0.6 ± 0.71 μmol/L; CA-125: ovarian cancer vs. benign ovarian tumor: 604.55 ± 865.84 vs. 86.71 ± 194.87 U/mL), which showed statistically significant differences (both P < 0.05). LPA with advanced sensitivity (92.68%), specificity (87.8%), positive predictive value (88.37%) and negative predictive value (92.31%) is compared with CA-125 in the diagnosis of ovarian cancer. The areas under the receiver operating characteristic curve are in the diagnosis of ovarian cancer (LPA: 0.925; CA-125: 0.779). Conclusion: LPA has greater value, and it is a better biomarker for diagnosis of EOC compared to CA-125. © 2018, Association of Gynecologic Oncologists of India.